Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: open surgery Clear all
Completed Phase 2 Interventional Results available

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

NCT02282345
View directory record Official record
Conditions
Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, HER2/Neu Negative, Invasive Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Talazoparib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Thoraflex™ Hybrid IDE Study

NCT02724072
View directory record Official record
Conditions
Aortic Aneurysm, Aortic Dissection, Aortic Rupture
Interventions
Thoraflex™ Hybrid Device
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 22, 2026, 4:56 PM EDT
Recruiting No phase listed Observational

Peripheral Bypass Trial for Completion Control

NCT06264843
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia
Interventions
MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes
Device
Lead sponsor
Medistim ASA
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 22, 2026, 4:56 PM EDT
Enrolling by invitation Not applicable Interventional

Comparing Surgical Management Methods of Atrial Fibrillation

NCT07100483
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Atrial Fibrillation Ablation
Procedure
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 4:56 PM EDT
Completed No phase listed Observational

LIFE Study: Least Invasive Fast-Track EVAR

NCT02224794
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Ovation® Abdominal Stent Graft Platform
Device
Lead sponsor
TriVascular, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 22, 2026, 4:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

NCT06686394
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar, Pertuzumab, Tucatinib
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
5
States / cities
Aurora, Colorado • Boston, Massachusetts • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 4:56 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Stellate Ganglion Blockade in Post-Menopausal Women

NCT02907983
View directory record Official record
Conditions
Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions
Stellate Ganglion Block Injection with Bupivicaine, Saline injection
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD

NCT04089943
View directory record Official record
Conditions
Peripheral Arterial Disease, Vascular Diseases, Peripheral, Arterial Occlusive Diseases, Atherosclerosis
Interventions
Revascularization operation, Control group
Procedure · Other
Lead sponsor
University of West Florida
Other
Eligibility
30 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Austin, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 4:56 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Adipose Derived Stem Cell Therapy for Autism

NCT01502488
View directory record Official record
Conditions
Autism
Interventions
Fat Harvesting and Stem Cell Injection
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
3 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 22, 2026, 4:56 PM EDT
Terminated Phase 4 Interventional Results available

Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

NCT03015961
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
EXPAREL and bupivacaine HCl, Bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 22, 2026, 4:56 PM EDT
Recruiting Phase 4 Interventional

A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults

NCT07679282
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Positive airway pressure (PAP) therapy, Sleep dental device, Atomoxetine-oxybutynin
Device · Drug
Lead sponsor
Sairam Parthasarathy
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Tucson, Arizona • Redwood City, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 4:56 PM EDT
Not yet recruiting Phase 4 Interventional

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

NCT07864480
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
Device · Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 4:56 PM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

NCT07499674
View directory record Official record
Conditions
Lung Cancer, Lung Metastases
Interventions
Abenacianine, Near Infrared (NIR) Imaging
Drug · Other
Lead sponsor
Vergent Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Duarte, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 4:56 PM EDT
Completed No phase listed Observational

Study Using the SpinalStim Device Following Lumbar Fusion Surgery

NCT03176303
View directory record Official record
Conditions
Lumbar Spine Degeneration
Interventions
SpinalStim
Device
Lead sponsor
Orthofix Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Johnstown, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial

NCT03350750
View directory record Official record
Conditions
Idiopathic Normal Pressure Hydrocephalus (INPH)
Interventions
programmable CSF shunt valve
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Albuquerque, New Mexico • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 22, 2026, 4:56 PM EDT
Active, not recruiting Phase 3 Interventional

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin
Biological · Procedure · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rapid Learning Healthcare System in Pediatric Surgery

NCT03131180
View directory record Official record
Conditions
Colorectal Disorders
Interventions
Rapid Learning Healthcare System
Other
Lead sponsor
Katherine Deans
Other
Eligibility
Up to 17 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional

Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

NCT02422979
View directory record Official record
Conditions
Recurrent Head and Neck Cancer
Interventions
PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2, PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer

NCT00367679
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Duarte, California • Rancho Mirage, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies

NCT05048082
View directory record Official record
Conditions
Lung Cancer
Interventions
pegsitacianine, Tumor resection surgery
Drug · Procedure
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Open-Label CA-008 (Vocacapsaicin) in Bunionectomy

NCT03885596
View directory record Official record
Conditions
Pain
Interventions
CA-008, Ketorolac, Acetaminophen IV, Fentanyl, Bupivacaine Hydrochloride, Lidocaine HCl, Celecoxib, Acetaminophen Oral, Lidocaine Hydrochloride, Exparel
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 22, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Results available

COMFORT: A Multicenter, Open-label, Randomized, Crossover Study

NCT02462720
View directory record Official record
Conditions
Varicose Veins
Interventions
Varithena®, Radiofrequency ablation
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Pensacola, Florida • Melrose Park, Illinois • Amherst, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 22, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Propanolol in Breast Cancer

NCT02596867
View directory record Official record
Conditions
Breast Cancer
Interventions
propanolol
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 22, 2026, 4:56 PM EDT
Recruiting Not applicable Interventional

Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Complex Aortic Aneurysms

NCT06834607
View directory record Official record
Conditions
Juxta Renal Abdominal Aortic Aneurysm Without Rupture, Complex Aortic Aneurysms, Aortic Aneurysm
Interventions
Physician Modified Aortic Endograft repair for complex aortic aneurysm
Device
Lead sponsor
Akhilesh Jain
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 22, 2026, 4:56 PM EDT